In Paxil Fraud Scheme, Glaxo Pays The Price

Law360, New York (March 29, 2006, 12:00 AM EST) -- GlaxoSmithKline PLC will fork over $14 million to U.S. states in order to settle allegations that the drug giant forced government health plans to pay inflated prices for its widely-used antidepressant Paxil in a fraudulent scheme to block generic versions of the drug from being made.

The suit and the settlement, filed yesterday in a Pennsylvania federal court, stemmed from charges that a series of baseless patent-infringement lawsuits brought by Glaxo against generic drug-makers was part of the company’s scheme to delay the introduction of cheaper...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.